Acute Radiation Syndrome (ARS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Acute radiation syndrome (ARS) is a complex of syndromes developed in humans due to short-duration whole-body exposure to ionizing radiation with doses higher than 0.7–1.0 Gy. The prodromal phase occurs within hours of exposure and may last up to 2 days. The latent phase is a transitional period in which the patient is asymptomatic. This may last as long as three weeks but is much shorter with higher radiation exposures. The illness phase produces overt clinical manifestations, including infection because of leukopenia, bleeding from thrombocytopenia, diarrhea, electrolyte imbalances, altered mental status, and shock. The death or recovery phase often occurs over weeks or months. Bone marrow syndrome (dose from 0.7 to 10.0 Gy), gastrointestinal syndrome (above 8.0 Gy), cardiovascular syndrome (above 20.0 Gy), central nervous system (or neurological) syndrome (above 80.0 Gy), and cutaneous (skin) syndrome (above 10.0 Gy)
·
As per Thelansis’ research which encompasses
both the secondary and primary research findings, the prevalence of ARS varies
between 1.3 to 8.4 /1,000,000 in different countries.
DM1 is categorized into four subtypes:
congenital, childhood, classic, and minimal/late-onset.
Thelansis’s “Acute Radiation Syndrome
(ARS) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Acute
Radiation Syndrome (ARS) treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Acute Radiation Syndrome (ARS) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Acute Radiation Syndrome (ARS) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
-1.jpg)
Comments
Post a Comment